Inventor · disambiguated record
Susan L. Kalled
Also filed as: KALLED SUSAN · KALLED SUSAN L
15 granted patents·15 pending applications·216 citations·filing 2001–2024
92Inventor score
Top patents by PatentIndex Score
30 records- 0196US9034324B2Anti-BCMA antibodiesKALLED SUSAN L·Filed 2010·Granted May 19, 2015·156 cites·22 claims
- 0292US11053305B2Fusion protein constructs comprising anti-C3d antibody and CR1 polypeptideQ32 BIO INC·Filed 2020·Granted Jul 6, 2021·6 cites·35 claims
- 0390US9545086B2BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disordersMACKAY FABIENNE·Filed 2008·Granted Jan 17, 2017·16 cites·17 claims
- 0490US9387237B2Methods of treating a patient having an autoimmune disorder by administering a soluble BCMABIOGEN IDEC INC·Filed 2014·Granted Jul 12, 2016·14 cites·21 claims
- 0590US2025282883A1Anti-bcma antibodiesBIOGEN MA INC·Filed 2024·Application pending·0 cites
- 0688US11053306B2Fusion protein constructs comprising anti-C3d antibody and factor HQ32 BIO INC·Filed 2020·Granted Jul 6, 2021·2 cites·28 claims
- 0781US8084030B2Method of treating a patient having an autoimmune disorder by administering an antibody that binds human BCMAKALLED SUSAN·Filed 2010·Granted Dec 27, 2011·6 cites·18 claims
- 0880US8617545B2Methods for use with BAFF antagonistsHSU YEN-MING·Filed 2006·Granted Dec 31, 2013·8 cites·7 claims
- 0977US9097726B2Methods of evaluating BAFFBIOGEN IDEC INC·Filed 2014·Granted Aug 4, 2015·1 cites·17 claims
- 1077US8685657B2Methods of evaluating BAFFBIOGEN IDEC INC·Filed 2013·Granted Apr 1, 2014·1 cites·19 claims
- 1177US2022213208A1Anti-bcma antibodiesBIOGEN MA INC·Filed 2021·Application pending·0 cites
- 1275US8202698B2Methods of evaluating BAFFHSU YEN-MING·Filed 2006·Granted Jun 19, 2012·3 cites·19 claims
- 1373US8415111B2Methods of evaluating BAFFHSU YEN-MING·Filed 2012·Granted Apr 9, 2013·1 cites·4 claims
- 1469US11111307B2Anti-BCMA antibodiesBIOGEN MA INC·Filed 2018·Granted Sep 7, 2021·0 cites·18 claims
- 1568US11879008B2Methods of treating complement mediated diseases with fusion protein constructs comprising anti-C3d antibody and a complement modulatorQ32 BIO INC·Filed 2021·Granted Jan 23, 2024·0 cites·32 claims
- 1666US7850967B2Method of treating a patient having an autoimmune disorder by administering an antibody that binds human BAFFRBIOGEN IDEC INC·Filed 2004·Granted Dec 14, 2010·2 cites·18 claims
- 1762US2024301043A1METHODS OF TREATING COMPLEMENT MEDIATED DISEASES WITH FUSION PROTEIN CONSTRUCTS COMPRISING ANTI-C3d ANTIBODY AND A COMPLEMENT MODULATORQ32 BIO INC·Filed 2023·Application pending·0 cites
- 1858US2017029518A1Anti-bcma antibodiesBIOGEN MA INC·Filed 2016·Application pending·0 cites
- 1955US2015125460A1Anti-bcma antibodiesBIOGEN IDEC INC·Filed 2015·Application pending·0 cites
- 2055US2014213470A1Methods for use with baff antagonistsGENENTECH INC·Filed 2013·Application pending·0 cites
- 2154US8828948B2Method of treating a patient having an autoimmune disorder by administering BAFFR polypeptideKALLED SUSAN·Filed 2011·Granted Sep 9, 2014·0 cites·27 claims
- 2253US2005158314A1Method of therapeutic administration of anti-CD40L compoundsFiled 2004·Application pending·0 cites
- 2352US2008254030A1Use of Baff to Treat Th2-Mediated ConditionsMACKAY CHARLES·Filed 2006·Application pending·0 cites
- 2452US2005244411A1BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disordersBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 2550US2007190053A1Treament of lupus nephritis with anti-CD40L compoundsKALLED SUSAN L·Filed 2006·Application pending·0 cites
- 2647US2003031668A1Treatment of immune complex disease with anti-CD40L antibodiesFiled 2002·Application pending·0 cites
- 2747US2003095967A1BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disordersFiled 2001·Application pending·0 cites
- 2846US2002071840A1Method of therapeutic administration of anti-CD40L compoundsFiled 2001·Application pending·0 cites
- 2943US2008267965A1Use of Bcma as an Immunoregulatory AgentKALLED SUSAN L·Filed 2003·Application pending·0 cites
- 3041US2011177093A1Use of bcma as an immunoregulatory agentBIOGEN INC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Susan L. Kalled files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →